Xeomin (incobotulinumtoxinA) coverage and authorization
Customize your policy alerts
Sign up for Viva Health Policy IC-0241 alerts
Get alerted when Policy IC-0241 changes without checking for updates manually.
Monitor payer policy activity
Defines prior authorization, dosing limits, indications, and renewal criteria for Xeomin (incobotulinumtoxinA) for multiple intramuscular/intradetrusor/intradermal/intraglandular indications for Viva Health members.
No material clinical or coverage changes in this revision.
Coverage Criteria
Initial Approval Universal Criteria
Covered when ALL of the following are met:
Prior authorization validity: initial approvals valid for 180 days (see authorization section).
Cervical Dystonia
Covered for cervical dystonia when ALL of the following are met:
Marked † indicates FDA‑approved indication.
Blepharospasm and Spasticity
Covered when ANY of the following applicable spastic conditions are present:
Prophylaxis for Chronic Migraines
Covered when ALL of the following are met:
Compendia‑referenced indication (‡).
Incontinence due to Neurogenic Detrusor Overactivity
Covered when ALL of the following are met:
Urodynamic confirmation required.
Overactive Bladder (OAB)
Covered when ALL of the following are met:
Compendia‑recommended context (‡).
Severe Primary Axillary Hyperhidrosis
Covered when ALL of the following are met:
Chronic Sialorrhea
Covered when ALL of the following are met:
FDA‑approved and compendia‑recommended contexts indicated where specified.
Ventral Hernia (preoperative)
Covered when ALL of the following are met:
Prior authorization validity may NOT be renewed for the ventral hernia indication; ventral hernia dosing/maximum differs (see dosing section).
Indication-specific coverage criteria
Covered when ALL of the following are met for each indication as specified below
Follow pediatric/adult dosing limits in dosing section (adults up to 400 units total; pediatric weight‑based limits apply).
Dose example: 50 units intradermally per axilla every 16 weeks.
Dose example: up to 200 units every 12 weeks.
Dose example: up to 200 units per treatment every 12 weeks.
Dose example: up to 100 units per treatment every 12 weeks.
Adult dosing example: 30 units per parotid and 20 units per submandibular gland per side (total 100 units); pediatric weight‑based dosing and repeat interval no sooner than every 16 weeks.
Prior authorization for Xeomin used preoperatively for ventral hernia is limited: initial prior authorizations follow standard rules but, per policy, prior authorization validity may NOT be renewed for the ventral hernia indication. Providers should plan one-time authorization and document the preoperative use for abdominal wall reconstruction as specified in the ventral hernia criteria.
Units of Xeomin (incobotulinumtoxinA) are specific to its preparation and assay method and are not interchangeable with units of other botulinum toxin products. Do not convert or substitute unit dosing between products when documenting or billing; dosing must use Xeomin units as stated in this policy.
Medicare Part B rules may supersede this policy when applicable. National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for CMS/Medicare Part B may apply and take precedence; providers should consult the Medicare Coverage Database and applicable contractor guidance for Part B billing and coverage requirements.
The policy specifies a maximum cumulative dose of 400 Units per treatment session for most indications. Coverage beyond this 400 Unit per-session limit is not supported, except where the policy explicitly notes an exception for the ventral hernia preoperative indication (see ventral hernia dosing guidance).
Coding and Billing
| HCPCS Unit | Indication-specific maximum billable units per dose and per # days as listed (e.g., Cervical Dystonia 200 units per dose / 84 days; Blepharospasm 100 units per dose / 84 days; Ventral Hernia 500 units per dose / N/A days; see policy for full per‑indication table). |
| J0588 | Injection, incobotulinumtoxinA, 1 unit; 1 billable unit = 1 unit |
| 00259-1605-xx | Xeomin 50 unit powder for injection; single-dose vial |
| 00259-1610-xx | Xeomin 100 unit powder for injection; single-dose vial |
| 00259-1620-xx | Xeomin 200 unit powder for injection; single-dose vial |
| G24.3 | Spasmodic torticollis |
| G24.5 | Blepharospasm |
| G25.89 | Other specified extrapyramidal and movement disorders |
| G35.A | Relapsing-remitting multiple sclerosis |
| G35.B0 | Primary progressive multiple sclerosis, unspecified |
| G35.B1 | Active primary progressive multiple sclerosis |
| G35.B2 | Non-active primary progressive multiple sclerosis |
| G35.C0 | Secondary progressive multiple sclerosis, unspecified |
| G35.C1 | Active secondary progressive multiple sclerosis |
| G35.C2 | Non-active secondary progressive multiple sclerosis |
| A59707 | Local Coverage Article: Billing and Coding: Botulinum Toxin Injections (NGS reference) |
| A57186 | Local Coverage Article: Billing and Coding: Botulinum Toxin Injections (Noridian) |
| A59809 | Local Coverage Article: Billing and Coding: Botulinum Toxin Injections (WPS) |
| A59726 | Local Coverage Article: Billing and Coding: Botulinum Toxins Injections (CGS) |
| A57185 | Local Coverage Article: Billing and Coding: Botulinum Toxin Injections (Noridian alternate) |
| A59714 | Local Coverage Article: Billing and Coding: Botulinum Toxin Injections (Palmetto GBA) |
| A57715 | Local Coverage Article: Billing and Coding: Botulinum Toxins (First Coast) |
| A58423 | Local Coverage Article: Billing and Coding: Botulinum Toxins (Novitas) |
Provider Actions and Documentation Requirements
Prior authorization required; initial 180 days, renewals 365 days
Prior authorization is required for Xeomin. Initial approvals are valid for 180 days (6 months); subsequent renewals may be authorized every 12 months (365 days) unless otherwise specified. Members must meet age and universal initial criteria (e.g., age ≥18 unless otherwise specified, no FDA‑labeled contraindications, and not receiving concurrent botulinum toxin therapy).
- Initial PA: 180 days (6 months)
- Renewal PA: 365 days (12 months)
- Member must meet age and universal initial criteria (see policy)
PA applies to administration billed with HCPCS J0588; NDCs/vial sizes noted
Prior authorization applies to administration of incobotulinumtoxinA billed with HCPCS code J0588 (Injection, incobotulinumtoxinA, 1 unit). NDCs and available single‑dose vial sizes (50, 100, 200 units) are listed for reference and billing.
- HCPCS: J0588 — Injection, incobotulinumtoxinA, 1 unit
- NDCs: 00259-1605-xx (50 units); 00259-1610-xx (100 units); 00259-1620-xx (200 units)
PA may be used based on indication, safety/efficacy, and cost (NQTL)
Prior authorization may be applied using the NQTL factor checklist — consideration is given based on the clinical indication, safety and efficacy evidence, and drug cost. These NQTL factors support use of PA for Xeomin.
- NQTL conclusions: Indication = Yes (consider PA); Safety/efficacy = Yes (consider PA); Cost = Yes (consider PA)
Document failure of specified conservative therapies prior to authorization
For bladder indications (neurogenic detrusor overactivity and OAB) and for severe primary axillary hyperhidrosis, prior authorization requires documentation of failure of specified conservative therapies before approval.
- Neurogenic detrusor overactivity: failed ≥1 month trial of two medications from antimuscarinic or beta‑adrenergic classes
- Overactive bladder: failed ≥1 month trial of two medications from antimuscarinic or beta‑adrenergic classes
- Axillary hyperhidrosis: failed ≥1 month trial of a topical agent (e.g., 20% aluminum chloride, glycopyrronium, etc.)
Continue other prophylactic modalities alongside Xeomin for chronic migraine
For chronic migraine prophylaxis, members are expected to continue other prophylactic modalities (behavioral therapy, pharmacotherapy, neuromodulation, trigger management, physical therapy) in conjunction with Xeomin rather than substituting them.
- Continue prophylactic interventions such as avoiding triggers, pharmacotherapy, behavioral therapy, neuromodulation, and physical therapy
No additional explicit step therapy requirements specified
No explicit step‑therapy (forced prior‑step) sequence is specified in this policy excerpt; the document does not present additional mandatory step requirements beyond the conservative therapy trials noted for certain indications.
Document baseline disease severity with objective measure for chronic migraine
For chronic migraine prophylaxis, the physician must document baseline disease severity using an objective validated tool (e.g., HIT‑6, monthly headache day counts, MIDAS, MPFID) as part of the prior authorization submission.
- Examples: Headache Impact Test (HIT‑6); monthly headache days (MHD); MIDAS; MPFID
Urodynamic testing confirming neurogenic detrusor overactivity required
For neurogenic detrusor overactivity, prior authorization requires documentation of urodynamic testing that confirms detrusor overactivity associated with a neurologic condition (e.g., spinal cord injury, multiple sclerosis).
- Urodynamic testing confirming detrusor overactivity associated with a neurologic condition is required
Document objective measures and functional improvement per indication
Providers must document objective, indication‑specific clinical response to support renewal and continuation. Examples include decreased tone on the Ashworth Scale for spasticity, reduction in monthly headache days or validated headache disability scores for migraine, and reduced incontinence episodes with periodic PVR assessment for bladder indications.
- Spasticity: validated tool such as Ashworth Scale or CGI showing decreased tone/resistance
- Chronic migraine: objective decrease in headache metrics (HIT‑6, MHD, MIDAS) and functional improvement
- Bladder indications: reduced incontinence episodes and periodic post‑void residual (PVR) assessments
- Hyperhidrosis/sialorrhea: documented reduction in sweat or saliva production and ADL improvement as applicable
PA consideration guided by NQTL factors (indication, safety/efficacy, cost)
Prior authorization may be considered based on the NQTL checklist factors; document the clinical indication, safety/efficacy rationale, and any cost considerations as relevant to the request.
Check for FDA‑labeled contraindications and concurrent botulinum toxin therapy
Requests may be denied or require additional documentation when members have FDA‑labeled contraindications such as hypersensitivity to any botulinum toxin product or active infection at the proposed injection site, or when the member is receiving concurrent treatment with another botulinum toxin.
- Contraindications: hypersensitivity to any botulinum toxin product or excipient; active infection at proposed injection site
- Concurrent botulinum toxin therapy: documentation that member is not receiving another botulinum toxin is required
Absence of documented objective improvement may prevent renewal
Lack of documented objective improvement on validated measurement tools (e.g., Ashworth Scale for spasticity; HIT‑6, MHD, MIDAS for migraine) or absence of documentation of functional improvement may prevent renewal and lead to denial.
- Validated tools cited: Ashworth Scale, HIT‑6, monthly headache days (MHD), MIDAS
Claims using primary G/M codes require a secondary G or I diagnosis code
Claims billed with primary G and M codes must include the required secondary G or I diagnosis code to be payable; failure to include the secondary code risks denial or non‑payment.
- Ensure primary G/M procedure claims include the required secondary G or I diagnosis code to avoid denial
Initial Therapy Criteria
Initial Therapy Criteria
Initial approval provided when universal and indication-specific criteria are met:
Initial prior authorization validity is 180 days; localization of injection sites with EMG/nerve stimulation/ultrasound is recommended.
Initial therapy dosing examples
Initial dosing where specified
Tailor dose and frequency to individual response.
Ventral hernia is an exception to the 400‑unit cumulative maximum and prior authorization renewals are not permitted for this indication.
Renewal and Repeat Dosing
Renewal Criteria
Renewal allowed when the following are met:
Renewals are valid for 365 days when criteria met.
Repeat dosing
Continuation/repeat dosing requirements per indication
Maximum cumulative dose per treatment session: 400 Units for most indications (ventral hernia exception up to 500 Units).
Step Therapy and Prior Conservative Treatments
| Indication | Required prior conservative therapy (documentation of failure required before authorization) | Notes / duration |
|---|---|---|
| Incontinence due to Neurogenic Detrusor Overactivity | ||
| Member has failed a ≥1 month trial of two medications from either the antimuscarinic (e.g., darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, trospium) or beta-adrenergic (e.g., mirabegron, vibegron) classes (documentation required) | ||
| Urodynamic testing confirming detrusor overactivity associated with a neurologic condition is required; trials must be ≥1 month each |
| Indication | Concurrent/prophylactic modalities expected | Step therapy status / requirement |
|---|---|---|
| Member continues to utilize prophylactic intervention modalities (e.g., trigger avoidance, pharmacotherapy, behavioral therapy, neuromodulation, physical therapy) | ||
| Continued use of other prophylactic modalities is expected alongside Xeomin; this is not framed as a strict prior-step failure but as concurrent management |
Quantity Limits
Site of Care and Procedural Guidance
Use EMG, nerve stimulation, or ultrasound to localize involved muscles for injections
When injecting muscles for spasticity or other muscular indications, localization of involved muscles with electromyographic (EMG) guidance, nerve stimulation, or ultrasound is recommended and should be used per the dosing/administration guidance.
- Localization methods: EMG guidance, nerve stimulation, or ultrasound
Background
Xeomin (incobotulinumtoxinA) is a botulinum toxin type A product administered via intramuscular, intradetrusor, intradermal, or intraglandular injection for a range of neurologic and autonomic conditions. The policy lists both FDA‑approved and compendia‑recommended uses and provides indication‑specific dosing, documentation, and authorization requirements. Localization techniques such as EMG, ultrasound, or nerve stimulation are recommended to guide injections and optimize targeting.
Definitions and Measurement Tools
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.